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Introduction
The small GTPase Ras (H-, K-, and N-Ras) activated by extra-
cellular signals exerts its cellular or physiological functions 
through binding to a variety of target proteins (Campbell et al., 
1998; Mitin et al., 2005). Raf is one of the best characterized 
target proteins of Ras. The Raf family consists of three members: 
Raf-1 (C-Raf), A-Raf, and B-Raf. They share the three con-
served regions CR1, 2, and 3. CR1 contains the Ras-binding 
and cysteine-rich domains (CRDs), both of which participate in 
binding to active Ras and membrane recruitment, whereas CR3 
encompasses the Ser/Thr protein kinase domain (Hagemann 
and Rapp, 1999; Mercer and Pritchard, 2003; Wellbrock et al., 
2004). The binding of active Ras to Raf triggers activation of 
the extracellular-regulated kinase (ERK)–MAPK pathway 
(Raf–MAPK and ERK kinase [MEK]–ERK), which partici-
pates in a variety of cellular, physiological, and pathological 
responses (Schaeffer and Weber, 1999; Chang and Karin, 2001; 
Pearson et al., 2001). For instance, the growth factor–induced 
activation of Ras leads to ERK pathway–mediated cell prolifer-
ation and morphogenesis during animal development. Onco-
genic Ras causes constitutive activation of the ERK pathway, 
resulting in cellular transformation and tumorigenesis.
The Ras–ERK pathway also regulates differentiation in 
a variety of cell types (Schramek, 2002). This pathway is es-
sential for NGF-induced neuronal differentiation in PC12 cells 
(Marshall, 1995). In contrast, this pathway, which is activated 
by serum mitogens or growth factors as well as by oncogenic 
Ras, negatively regulates skeletal muscle cell differentiation 
(Olson et al., 1987; Bennett and Tonks, 1997). Skeletal muscle 
cell differentiation necessitates irreversible cell cycle arrest in 
G0 phase, the expression of a battery of muscle-specifi  c genes, 
and cell fusion to form multinucleated myotubes (Endo and 
Nadal-Ginard, 1987; Lassar et al., 1994). The tumor suppressor 
protein Rb is indispensable for cell cycle arrest (Endo and Goto, 
1992; Schneider et al., 1994; Novitch et al., 1996), whereas MyoD 
family and MEF2 family transcription factors bring about the 
myogenic program by inducing muscle-specifi  c gene expres-
sion (Black and Olson, 1998; Tapscott, 2005). The negative 
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  R
as activates Raf, leading to the extracellular-
  regulated kinase (ERK)–mitogen-activated protein 
kinase pathway, which is involved in a variety of 
cellular, physiological, and pathological responses. Thus, 
regulators of this Ras–Raf interaction play crucial roles in 
these responses. In this study, we report a novel regulator 
of the Ras–Raf interaction named DA-Raf1. DA-Raf1 is a 
splicing isoform of A-Raf with a wider tissue distribution 
than A-Raf. It contains the Ras-binding domain but lacks 
the kinase domain, which is responsible for activation of 
the ERK pathway. As inferred from its structure, DA-Raf1 
bound to activated Ras as well as M-Ras and interfered 
with the ERK pathway. The Ras–ERK pathway is essential 
for the negative regulation of myogenic differentiation in-
duced by growth factors. DA-Raf1 served as a positive 
regulator of myogenic differentiation by inducing cell cycle 
arrest, the expression of myogenin and other muscle-
speciﬁ  c proteins, and myotube formation. These results im-
ply that DA-Raf1 is the ﬁ  rst identiﬁ  ed competent, intrinsic, 
dominant-negative antagonist of the Ras–ERK pathway.
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regulation of skeletal muscle cell differentiation by the Ras–
ERK pathway is ascribable to interference with the expression 
or functions of MyoD and MEF2 families (Lassar et al., 1989; 
Winter and Arnold, 2000; Perry et al., 2001; Tortorella et al., 
2001) and with the activation of Rb (Mittnacht et al., 1997; 
Peeper et al., 1997; Lee et al., 1999). Thus, it is reasonable that 
the deprivation of serum mitogens or growth factors leads to in-
activation of the Ras–ERK pathway and, consequently, results 
in skeletal muscle cell differentiation. However, detailed mech-
anisms of this inactivation of the Ras–ERK pathway have not 
been fully elucidated.
The activity of the Ras–ERK pathway is tightly controlled 
through the coordinated action of both positive and negative 
regulators that function at various levels of the pathway and at 
different time points of the responses. Recently, several sup-
pressor proteins of the Ras–ERK pathway have been identifi  ed. 
These include Sprouty (Spry)/Spred proteins (Wakioka et al., 2001; 
Kim and Bar-Sagi, 2004; for review see Mason et al., 2006), 
RKIP (Raf kinase inhibitor protein; Yeung et al., 1999; Odabaei 
et al., 2004), and IMP (Matheny et al., 2004; for review see Ory 
and Morrison, 2004). Both Spry and RKIP bind to Raf to inhibit 
the ERK pathway by preventing the binding of MEK. Spry also 
intercepts growth factor receptor–Ras–ERK signaling by inter-
acting with distinct proteins, depending on the signaling. In 
contrast, IMP uncouples signal transduction from Raf to MEK by 
inactivating the scaffold protein KSR (kinase suppressor of Ras). 
However, it has been poorly understood whether regulatory 
proteins that directly bind to Ras to prevent the ERK pathway 
are present.
M-Ras, a member of the Ras family small GTPases, in-
duces the reorganization of actin cytoskeleton, cellular trans-
formation, inhibition of myogenic differentiation, and neuronal 
differentiation in PC12 cells (Matsumoto et al., 1997; Quilliam 
et al., 1999; Kimmelman et al., 2002; Sun et al., 2006). To eluci-
date the molecular mechanisms of these cellular functions of 
M-Ras, we have identifi  ed proteins that bind to a constitutively 
activated mutant of M-Ras. One of them was a novel splicing 
isoform of A-Raf, designated as DA-Raf1, which contains the 
Ras-binding domain (RBD) but lacks the kinase domain. DA-Raf1 
bound to both active Ras and M-Ras and interfered with the 
ERK pathway. Its expression level was prominently elevated, 
and it positively regulated myogenic differentiation by inducing 
cell cycle arrest, muscle-specifi  c protein expression, and myo-
tube formation. Thus, DA-Raf1 is the fi  rst identifi  ed intrinsic 
dominant-negative antagonist of the Ras–ERK pathway.
Results
DA-Raf1 binds to active Ras and M-Ras
To elucidate the molecular mechanisms of the cellular functions 
of M-Ras, we have screened a mouse brain cDNA library by a 
yeast two-hybrid system and cloned cDNAs of proteins that 
bind to a constitutively activated mutant of M-Ras(G22V) 
(Gly22 is substituted by Val). These proteins include B-Raf, 
RalGDS, Rgl2, AF-6, and a C terminus–truncated isoform of 
A-Raf consisting of N-terminal 186 amino acids (Fig. 1 A). We 
designate this truncated protein DA-Raf1 (deleted A-Raf).
DA-Raf1 bound not only to M-Ras(G22V) but also to 
H-Ras (both wild type and a constitutively active G12V mutant), 
whereas it did not bind to their dominant-negative mutants 
M-Ras(S27N) and H-Ras(S17N), as determined by a two-hybrid 
binding assay (Fig. 1 A). A pull-down assay also showed that 
GST-tagged DA-Raf1 bound to the constitutively active mutants 
of M-Ras and H-Ras as well as v–K-Ras but not to their dominant-
negative mutants (Fig. 1 B). Moreover, immunoprecipitation 
of myc-tagged H-Ras(G12V) or M-Ras(G22V) exogenously 
expressed in COS-1 cells with the anti-myc mAb myc1-9E10 
resulted in the coprecipitation of HA-tagged DA-Raf1 (Fig. 1 C), 
indicating their interaction in vivo. Immunoprecipitation of 
H-Ras in differentiating C2C12 skeletal muscle cell lysates and 
in mouse brain extracts brought about the coprecipitation of 
endogenous DA-Raf1 (see Fig. 5 G), also implying the binding 
of endogenous Ras and DA-Raf1.
Immunofl  uorescent staining in combination with myc 
epitope tagging located both H-Ras(G12V) and M-Ras(G22V) 
to membrane ruffles and H-Ras(G12V) to vesicles such as 
macropinosomes as well (Bar-Sagi and Feramisco, 1986) as in 
C2C12 myoblasts (Fig. S1 A, available at http://www.jcb.org/
cgi/content/full/jcb.200703195/DC1). HA–DA-Raf1 was co-
localized with the constitutively active H-Ras and M-Ras to these 
membrane-associated structures (Fig. S1 A). On the other hand, 
in serum-starved C2C12 cells expressing wild-type myc–H-Ras 
or M-Ras, HA–DA-Raf1 was diffusely distributed throughout 
the cytoplasm and coincided with neither wild-type H-Ras nor 
M-Ras (Fig. 1 D). When the cells were stimulated with FBS or 
FGF2, however, HA–DA-Raf1 was colocalized with the acti-
vated H-Ras and M-Ras to the plasma membrane or vesicle 
membrane–associated structures (Fig. 1 D). In contrast, if myc–
H-Ras(S17N) or M-Ras(S27N) was expressed, the membrane 
ruffl  es or vesicles were not formed even by stimulation with FBS 
or FGF2 (Fig. S1 B). HA–DA-Raf1 was diffusely distributed 
throughout the cytoplasm and coexisted with neither H-Ras(S17N) 
nor M-Ras(S27N) in these stimulated cells (Fig. S1 B). These 
results support the interaction of DA-Raf1 with active Ras and 
M-Ras in vivo.
DA-Raf1 and 2 are generated 
by alternative splicing of Araf pre-mRNA
All known Raf family proteins (Raf-1, A-Raf, and B-Raf) have 
three conserved regions: CR1, 2, and 3 (Fig. 2 A; Hagemann 
and Rapp, 1999; Mercer and Pritchard, 2003; Wellbrock et al., 
2004). CR1 contains the RBD and CRD, both of which par-
ticipate in binding to active Ras and membrane recruitment, 
whereas CR3 represents the kinase domain. The amino acid 
sequence of DA-Raf1 deduced from its nucleotide sequence 
indicated that DA-Raf1 exactly corresponds to the N-terminal 
186 amino acids of A-Raf, which contains CR1 but lacks CR2 
and 3 (Fig. 2 A). Comparison of the nucleotide sequence of 
mouse DAraf1 cDNA with that of the genomic sequence of the 
mouse Araf gene revealed that DAraf1 mRNA is generated by 
the alternative splicing of Araf pre-mRNA (Fig. 2 B). DAraf1 
cDNA retains intron 6–7 linked to exon 6 and, consequently, 
gives rise to the termination codon TAG starting from the sec-
ond nucleotide of intron 6–7 (Fig. 2, B and C). Poly(A) tail is DA-RAF1 IS REQUIRED FOR MYOGENIC DIFFERENTIATION • YOKOYAMA ET AL. 783
added 12 bases downstream of the putative poly(A) addition 
signal AATAAA.
To confi  rm that DAraf1 is actually expressed in vivo, we 
conducted RT-PCR and Northern blotting. Quantitative RT-PCR 
using the sense primer (nt 62–79), which is common to both 
DAraf1 and Araf, and the antisense primer (nt 620–639), which is 
specifi  c for DAraf1 (Fig. 3 A), amplifi  ed major 578-bp and minor 
695-bp DNA bands from mRNAs of various mouse tissues 
(Fig. 3 B). Nucleotide sequences of these DNAs indicated that the 
former band represented expected DAraf1, whereas the latter band 
corresponded to the DNA containing intron 5–6 (117 nt) between 
exons 5 and 6. The retention of intron 5–6 generates the termina-
tion codon TGA starting from the second nucleotide of intron 5–6 
(Fig. 2, B and C). We refer to this splicing isoform as DA-Raf2. 
DAraf2 encodes a protein consisting of the N-terminal 153 amino 
acids of A-Raf, which also includes RBD and CRD (Fig. 2 A). 
Examination of the genomic sequences of rat and human Araf 
genes revealed that both of the genes have exon–intron junctional 
arrangements and sequences very similar to those of the 
mouse gene. Consequently, mRNAs encoding DA-Raf1 and 2 
seem to be generated by the alternative splicing of rat and hu-
man Araf pre-mRNAs as well (Fig. S2, A and B; available at 
http://www.jcb.org/cgi/content/full/jcb.200703195/DC1). Indeed, 
we have cloned rat and human DAraf1 cDNAs by RT-PCR from 
rat PC12 cells and human HeLa cells, respectively.
DA-Raf1 is widely expressed
Quantitative RT-PCR showed that both DAraf1 and DAraf2 
were ubiquitously expressed in a variety of tissues examined 
and that they were prominently expressed in the brain and heart, 
among others (Fig. 3 B). In contrast, Araf had more limited tis-
sue distribution. It was most highly expressed in the liver among 
the tissues examined, as has been previously reported (Huleihel 
et al., 1986), whereas it was scarcely expressed in skeletal muscle 
(Fig. 3 B). Braf was also highly expressed in the brain, whereas 
Raf1 was widely expressed except in the brain. Next, we con-
ducted Northern blotting with probe 1, which can hybridize to 
DAraf1, DAraf2, and Araf mRNAs in common, and conducted 
blotting with probe 2, which specifi  cally recognizes DAraf1 
mRNA (Fig. 3, A and C). DAraf1 mRNA (1.65 kb) and DAraf2 
mRNA (1.35 kb) were abundantly present in the brain and heart 
and moderately in other tissues, which is consistent with the 
results of RT-PCR analysis. On the other hand, Araf mRNA 
(2.4 kb) was expressed in the liver at a moderate level and had 
Figure 1.  Binding of DA-Raf1 to M-Ras and Ras proteins. 
(A) Yeast two-hybrid binding assay detecting the binding of 
DA-Raf1 and other proteins to M-Ras and H-Ras. The binding 
was detected by β-galactosidase colony-lift ﬁ   lter assay. wt, 
wild-type. (B) Pull-down assay with GST–DA-Raf1. Binding of 
myc-tagged H-Ras, M-Ras, and v–K-Ras in COS-1 cell lysates 
to GST–DA-Raf1 was detected by immunoblotting with the 
anti-myc mAb myc1-9E10. (C) Coimmunoprecipitation assay. 
Myc-tagged H-Ras and M-Ras in COS-1 cell lysates were 
immunoprecipitated with the anti-myc mAb, and coprecipitated 
HA–DA-Raf1 was detected by immunoblotting with the anti-HA 
tag pAb. (D) Colocalization of DA-Raf1 with activated H-Ras 
and M-Ras to the membrane rufﬂ  es and vesicles. C2C12 myo-
blasts cotransfected with myc–Hras or myc–Mras and HA–
DAraf1 were serum starved and stimulated with 10% FBS or 
50 ng/ml FGF2 for 30 min. The localization of myc–H-Ras 
or myc–M-Ras and HA–DA-Raf1 was detected by staining 
with the anti-myc mAb (green) and the anti-HA tag pAb (red), 
respectively. Their merged images are shown. Arrows point to 
the membrane rufﬂ  es where DA-Raf1 is colocalized with acti-
vated H-Ras or M-Ras. Arrowheads indicate the vesicles where 
DA-Raf1 is colocalized with activated H-Ras. Bars, 10 μm.JCB • VOLUME 177 • NUMBER 5 • 2007  784
a more restricted tissue distribution (Fig. 3 C). Immuno  blotting 
analysis with an anti–DA-Raf pAb showed that DA-Raf1 pro-
tein was abundantly present in the brain and moderately in the 
heart, skeletal muscle, uterus, and spleen (Fig. 3 D). DA-Raf2 
was also detected at least in the brain. In contrast, A-Raf was pre-
dominantly present in the liver and spleen, as corroborated by 
immunoblotting with an anti–A-Raf pAb (Fig. 3 D). Collec-
tively, DAraf1 mRNA and protein are actually present in mouse 
tissues with a wider tissue distribution than A-Raf.
DA-Raf1 antagonizes the Ras–ERK pathway
The structure of the DA-Raf1 protein, which contains both 
RBD and CRD but lacks the kinase domain, suggests that it serves 
as an intrinsic dominant-negative antagonist of the Ras–ERK 
pathway and possibly as an antagonist of other Ras-activated 
signaling pathways such as Ras–phosphatidylinositol 3-kinase 
(PI3K)–Akt signaling. To assess this possibility, we transfected 
NRT9 cells (the mouse NIH3T3 fi  broblasts stably transformed 
with the oncogenic v-Kras gene) with myc-tagged DAraf1 
cDNA and selected eight stable transfectants (NRT/DR1–8). The 
expression of exogenous myc–DA-Raf1 in these cell lines was 
detected by immunoblotting with the anti-myc mAb (Fig. 4 A). 
The levels of ERK activation and Akt activation were esti-
mated by immunoblotting with an antiphospho-ERK1/2 mAb 
and an antiphospho-Akt pAb, respectively. NRT9 and mock-
transfected NRT9 cells had much higher activating phosphory-
lation levels of ERK1/2 than did normal NIH3T3 cells, whereas 
all of the NRT/DR cell lines showed ERK1/2 phosphorylation 
levels comparable with that in normal NIH3T3 cells (Fig. 4 A). 
In contrast, activating phosphorylation levels of Akt in NRT9 
and mock-transfected NRT9 cells were almost equivalent to that 
in normal NIH3T3 cells. This is consistent with the results that 
K-Ras effi  ciently activates Raf but not PI3K (Yan et al., 1998; 
Voice et al., 1999). The Akt phosphorylation levels were sub-
stantially unchanged in any of the NRT/DR cell lines (Fig. 4 A). 
Transiently expressed myc–DA-Raf1 in C2C12 myoblasts also 
Figure 2.  Domain structure of DA-Raf1/2 and splicing patterns of Araf/DAraf pre-mRNA. (A) Functional domains of Raf proteins and DA-Raf1/2. 
The numbers indicate amino acid residues of mouse proteins. (B) Alternative splicing of Araf/DAraf pre-mRNA generating Araf and DAraf1/2 mRNAs. 
Pink boxes, exons; purple boxes, introns; yellow boxes, introns retained in DAraf1/2 mRNAs but not in Araf mRNA; asterisks, termination codons for DA-Raf2 
(in intron 5–6) and DA-Raf1 (in intron 6–7). (C) Nucleotide sequence of exons (red) and introns (blue) retained in mouse DAraf1/2 mRNAs and the corre-
sponding amino acid sequence. Asterisks in intron 5–6 and intron 6–7 represent termination codons of DAraf2 and DAraf1 mRNAs, respectively. Red and 
green underlines indicate putative poly(A) addition signals of DAraf1 and DAraf2 mRNAs, respectively.DA-RAF1 IS REQUIRED FOR MYOGENIC DIFFERENTIATION • YOKOYAMA ET AL. 785
reduced the ERK1/2 phosphorylation level but not the Akt phos-
phorylation level (Fig. S3 A, available at http://www.jcb.org/
cgi/content/full/jcb.200703195/DC1). Consequently, the exog-
enously expressed DA-Raf1 is likely to antagonize the Ras–ERK 
pathway but not Ras–PI3K–Akt signaling.
Activation of the Raf-mediated ERK pathway by onco-
genic Ras induces transformation in mouse fi  broblasts (Kolch 
et al., 1991; Cowley et al., 1994; Mansour et al., 1994). Because 
the activation of ERK was abrogated by DA-Raf1 expression, 
we examined whether the v–K-Ras–induced transformed phe-
notype in NRT9 cells was suppressed by DA-Raf1. Normal 
NIH3T3 cells contained well-developed actin stress fi  bers and 
showed an extended fl  attened cell shape. Although NRT9 cells 
exhibited transformed morphology (i.e., the loss of stress fi  bers 
and consequent round cell shape), all of the NRT/DR cell lines 
restored the normal fl  attened cell shape with stress fi  bers (Fig. 4 B). 
Next, we analyzed the cell proliferation rate under a serum star-
vation condition in 0.5% FBS by counting the cell number. NRT9 
and mock-transfected NRT9 cells showed growth rates several 
fold higher than that of normal NIH3T3 cells, whereas all of the 
NRT/DR cell lines exhibited growth rates similar to or lower 
than that of NIH3T3 cells (Fig. 4 C).
When NRT9 and mock-transfected NRT9 cells were cul-
tured for 7 d after reaching confl  uence in the growth medium, 
they formed innumerable foci, which merged with each other 
because of the loss of contact inhibition of transformed cells 
(Fig. S3 B). In contrast, all of the NRT/DR cell lines as well as 
normal NIH3T3 cells scarcely formed foci. We further analyzed 
the anchorage-independent growth potential of these cells in 
soft agar. Although  10–15% of NRT9 and mock-transfected 
NRT9 cells formed colonies, all of the NRT/DR cell lines formed 
colonies at very low effi  ciencies (Fig. S3 C). Next, we injected 
1 × 10
6 cells subcutaneously into dorsal fl  anks of athymic nude 
mice. All mice (three out of three) injected with NRT9 or mock-
transfected NRT9 cells formed tumors 6–7 mm in diameter 
within 4 wk after the injection (Fig. S3 D). However, no mice 
injected with normal NIH3T3 cells or any of the NRT/DR cell 
lines formed tumors even 8 wk after the injection (Fig. S3 D). 
These results indicate that the exogenously expressed DA-Raf1 
can suppress all of the transformed phenotypes, including 
tumorigenicity induced by oncogenic Ras.
DA-Raf1 prominently induced during skeletal 
myocyte differentiation is responsible 
for reduction in MEK–ERK activity
The Ras–ERK pathway negatively regulates skeletal muscle 
cell differentiation by suppressing the expression or functions 
of the muscle-specifi  c transcription factors MyoD and MEF2 
Figure 3.  Expression of DAraf1/2 mRNAs 
and the proteins in mouse tissues. (A) DAraf1/2 
mRNAs together with primers and probes used 
for RT-PCR and Northern blotting, respectively. 
Pink boxes, coding regions including termina-
tion codons; purple boxes, untranslated regions; 
Ex, exon; Int, intron. Asterisks represent termi-
nation codons. The numbers indicate nucle-
otide numbers starting from the 5′ ends of the 
cDNAs. (B) Quantitative RT-PCR detecting 
DAraf1/2, Araf, Braf, and Raf1 mRNAs. Glycer-
aldehyde 3-phosphate dehydrogenase (Gapdh) 
mRNA is shown as a standard. (C) Northern 
blotting detecting DAraf1/2 and Araf mRNAs 
with probe 1 and DAraf1 mRNA with probe 2. 
Ethidium bromide (EtBr) staining of a gel shows 
28S and 18S rRNAs as a standard. (D) Immuno-
blotting detecting DA-Raf1/2 and A-Raf proteins 
with the anti–DA-Raf pAb. The A-Raf bands were 
veriﬁ   ed by immunoblotting with the anti–A-Raf 
pAb. Each lane contains 50 μg of proteins. The 
asterisks indicate unidentiﬁ  ed extra protein bands 
reacted with the anti–DA-Raf pAb.JCB • VOLUME 177 • NUMBER 5 • 2007  786
(Lassar et al., 1989; Winter and Arnold, 2000; Perry et al., 2001; 
Tortorella et al., 2001). This suppression results in the aborted 
expression of myogenin, which induces muscle differentiation. 
Thus, to assess the involvement of DA-Raf1 in the regulation 
of skeletal muscle cell differentiation, we fi  rst analyzed the ex-
pression of DAraf1 during the differentiation of C2C12 skeletal 
muscle cells by quantitative RT-PCR and immunoblotting. 
Undifferentiated myoblasts terminally differentiate to form multi-
nucleated myotubes by cell fusion by shift from the mitogen-rich 
growth medium containing 10% FBS to the mitogen-poor differen-
tiation medium containing 5% horse serum. Well-differentiated 
myotubes are developed by 96 h under this culture condition. 
DAraf1 mRNA was present at a low level in myoblasts but was 
markedly induced about 10-fold during differentiation (Fig. 5, 
A and B). Myog mRNA was almost absent in myoblasts but 
highly induced during differentiation in accordance with the 
DAraf1 expression (Fig. 5, A and B). Immunoblotting showed 
that DA-Raf1 was almost absent in myo  blasts but prominently 
induced during differentiation (Fig. 5, C and D). Similarly, 
myogenin and late muscle-specific proteins, myosin heavy 
chain (MyHC) and troponin T (TnT), were also induced (Fig. 5, 
C and D). Although the band derived from DAraf2 mRNA was 
detected by RT-PCR, DA-Raf2 protein was hardly detected 
by immunoblotting even in differentiated C2C12 cells, which is 
different from in the brain. The increased rate of DA-Raf1 pro-
tein during differentiation was much higher than that of DAraf1 
mRNA. In contrast, the amounts of Raf-1, B-Raf, and A-Raf 
were almost constant during differentiation (Fig. 5, C and D). 
These results suggest the possibility that DA-Raf1 positively 
regulates skeletal muscle cell differentiation.
In proliferating myoblasts, the activating phosphorylation 
of MEK and ERK was easily detected by immunoblotting with 
an antiphospho-MEK1/2 pAb and the antiphospho-ERK1/2 
mAb, respectively (Fig. 5 E). In contrast, phospho-Akt was 
marginally present in myoblasts. The phosphorylation levels of 
both MEK and ERK were reduced, whereas that of Akt was ele-
vated during differentiation (Fig. 5 E). These results are consis-
tent with previous studies (Rommel et al., 1999; Tortorella 
et al., 2001). Immunoprecipitated B-Raf from myoblasts effi  -
ciently phosphorylated MEK, but the kinase activity was mark-
edly diminished during differentiation (Fig. 5 F). In contrast, 
immunoprecipitated Raf1 and A-Raf scarcely phosphorylated 
MEK regardless of the differentiation stage (Fig. 5 F and 
not depicted). These results are compatible with the notion that 
B-Raf is the main activator of MEK in most cell types (Mercer 
and Pritchard, 2003; Wellbrock et al., 2004). DA-Raf1 was not 
coimmunoprecipitated with H-Ras in myoblasts (Fig. 5 G). As 
differentiation proceeded, however, DA-Raf1 was coimmuno-
precipitated with H-Ras at the level similar to that in the brain 
(Fig. 5 G). In contrast, B-Raf was coimmunoprecipitated with 
H-Ras in myoblasts, and the amounts of precipitated B-Raf de-
creased as differentiation proceeded (Fig. 5 G). Collectively, 
these results imply that the decrease in MEK–ERK activity dur-
ing C2C12 cell differentiation is ascribed to the retardation of 
B-Raf activity and that the association of DA-Raf1 with Ras is 
likely to be responsible for the decline in Ras–B-Raf interaction 
and the consequent reduction in B-Raf–MEK–ERK activity during 
the differentiation.
Highly expressed DA-Raf1 induces skeletal 
myocyte differentiation
Because DA-Raf1 seems to negatively regulate the B-Raf– 
MEK–ERK pathway during C2C12 cell differentiation, it may 
be involved in the induction of differentiation. Skeletal muscle 
cell differentiation entails cell cycle arrest in G0 phase together 
with muscle-specifi  c gene expression and myotube formation. 
Figure 4.  Suppression of v–K-Ras–induced ERK activation, morphological 
alteration, and facilitated proliferation rate by DA-Raf1. (A) Suppression of 
ERK phosphorylation without affecting Akt phosphorylation in NRT/DR1–8 
cells. Proteins were detected by immunoblotting. NRT9/mock, mock-transfected 
NRT9 cells; P-ERK1/2, ERK1/2 with activating phosphorylation on Thr202 
and Tyr204, P-Akt, Akt with activating phosphorylation on Ser473. (B) Re-
covery of actin stress ﬁ  bers and extended ﬂ  attened cell shape in NRT/DR 
cells. Stress ﬁ  bers were detected by staining with rhodamine-phalloidin. 
(C) Reduction of the proliferation rate in NRT/DR cells. Cells were cultured 
in DME containing 0.5% FBS for the indicated times. The values are means ± 
SD (error bars) of three independent experiments.DA-RAF1 IS REQUIRED FOR MYOGENIC DIFFERENTIATION • YOKOYAMA ET AL. 787
To examine whether DA-Raf1 is implicated in the induction of 
cell cycle arrest, C2C12 cells were transfected with HA–DAraf1, 
and proliferating cells in S phase were detected by the incorpo-
ration of BrdU in the nuclei. DAraf1 expression markedly reduced 
the ratio of BrdU-incorporating cells (Fig. 6, A and B).
Next, we addressed whether DA-Raf1 participated in 
the induction of myogenin and late muscle-specific protein 
expression. The ratio of myogenin-expressing cells was facilitated 
1.5–2-fold by the transfection of DAraf1 during 48–72 h in the 
differentiation medium (Fig. 6, C and D). The transfection of 
DAraf1 also elevated the ratio of MyHC-expressing cells (Fig. 6, 
E and F) and TnT-expressing cells  (Fig. 6, G and H) two- to sev-
eral fold during differentiation. The effects of DAraf1 transfec-
tion to induce myogenin and the late muscle-specifi  c proteins 
were more obvious around 48–72 h after the transfection than at 
later time points probably because of the up-regulation of endog-
enous DA-Raf1 protein in control cells and breakdown of the 
transfected plasmids expressing DAraf1 in the process of time. 
Figure 5.  Prominent induction of DA-Raf1 
and reduction in B-Raf–MEK–ERK activities dur-
ing myogenic differentiation of C2C12 cells. 
(A) Induction of DAraf1/2 and Myog mRNAs 
during C2C12 cell differentiation detected by 
RT-PCR. (B) Relative amounts of the mRNAs. 
The amounts of DAraf1 and Myog mRNAs are 
normalized with that of Gapdh mRNA. The 
amounts of each mRNA are indicated as multi-
ples of the amount at 24 h. The values are 
means ± SD (error bars) of three independent 
experiments. *, P < 0.05; **, P < 0.01 by 
t test compared with the corresponding mRNA 
at 24 h. (C) Induction of DA-Raf1 and muscle-
speciﬁ  c proteins (myogenin, MyHC, and TnT) 
during C2C12 cell differentiation detected 
by immunoblotting. β-Tubulin is shown as a 
standard. (D) Relative amounts of the proteins. 
The amounts of each protein are indicated as 
multiples of the amount at 24 h. The values are 
means ± SD of three independent experiments. 
(E) Decrease in MEK and ERK phosphorylation 
and increase in Akt phosphorylation during 
differentiation. MEK1/2, phospho-MEK1/2, 
ERK1/2, phospho-ERK1/2, Akt, and phospho-
Akt were detected by immunoblotting. (F) Re-
duction in MEK phosphorylation by B-Raf. 
B-Raf and Raf1 were immunoprecipitated with 
anti–B-Raf and anti-Raf1, respectively. Their 
in vitro kinase assay was conducted by using 
MEK1 as a substrate. (G) Binding of DA-Raf1 
to H-Ras in differentiated C2C12 cells. H-Ras 
was immunoprecipitated with anti–H-Ras from 
C2C12 cells cultured in the differentiation me-
dium (DM) and from mouse brain. Precipitated 
H-Ras and coprecipitated DA-Raf1 and B-Raf 
as well as DA-Raf1 and B-Raf in brain extract 
were detected by immunoblotting.JCB • VOLUME 177 • NUMBER 5 • 2007  788
Therefore, highly expressed DA-Raf1 can bring on the myogenic 
differentiation program by inducing the cell cycle arrest and 
expression of myogenin and late muscle-specifi  c proteins.
Intrinsic DA-Raf1 induces skeletal 
myocyte differentiation by suppressing 
the ERK pathway
We further examined the role of endogenous DA-Raf1 by RNAi 
through expression of the two siRNAs, M1 and M2, which target 
the sequences in the 3′ untranslated regions of mouse DAraf1/2 
mRNAs. Expression of these siRNAs markedly reduced the 
amount of endogenous DA-Raf1 protein during the differentia-
tion of C2C12 cells (Fig. 7 A). In contrast, expression of the other 
two siRNAs, R1 and R2, targeting rat DAraf1/2 mRNA  sequences, 
which are distinct from the mouse counterparts, did not affect the 
amount of DA-Raf1 protein in C2C12 cells (Fig. 7 A).
C2C12 cells cultured in the differentiation medium for 
48 h became quiescent, and only  2% of the mock-transfected 
control cells incorporated BrdU for a further 8 h. However, ex-
pression of the mouse-specifi  c siRNAs M1 and M2 resulted in 
BrdU incorporation in  8–12% of the cells for 8 h after the 
48-h culture in the differentiation medium (Fig. 7, B and C). On 
the other hand, expression of the rat-specifi  c R1 and R2 did not 
facilitate the BrdU incorporation (Fig. 7, B and C). These re-
sults indicate that intrinsic DA-Raf1 is required for the cell cycle 
arrest that is indispensable for skeletal myocyte differentiation.
When the mouse-specifi  c siRNA M1 was expressed, the 
ratio of myogenin-expressing cells strikingly decreased during 
Figure 6.  Induction of the myogenic differentiation 
phenotype in C2C12 cells by highly expressed DA-
Raf1. (A) Induction of the cell cycle arrest in C2C12 
cells exogenously expressing DAraf1. C2C12 cells 
were transfected with HA–DAraf1 and incubated with 
BrdU for 2 h. The anti-HA staining detecting the expres-
sion of HA–DA-Raf1 (green) is merged with anti-BrdU 
staining (red). (B) Ratio of the BrdU-incorporating 
C2C12 cells in the analysis of A. (C) Facilitation of 
myogenin expression in C2C12 cells exogenously ex-
pressing DAraf1. The cells were cultured in the differenti-
ation medium. Control EGFP ﬂ  uorescence (green) or 
anti-HA staining detecting the expression of HA–DA-
Raf1 (green) is merged with antimyogenin staining (red). 
(D) Ratio of the myogenin-expressing cells in the analysis 
of C. (E) Promotion of MyHC expression in C2C12 cells 
exogenously expressing DAraf1. Control EGFP ﬂ  uores-
cence (green) or anti-HA staining detecting the expres-
sion of HA–DA-Raf1 (green) is merged with anti-MyHC 
staining (red). (F) Ratio of the MyHC-expressing cells in 
the analysis of E. (G) Facilitation of TnT expression in 
C2C12 cells exogenously expressing DAraf1. Control 
EGFP ﬂ  uorescence (green) or anti-HA staining detecting 
the expression of HA–DA-Raf1 (green) is merged with 
anti-TnT staining (red). (H) Ratio of the TnT-expressing cells 
in the analysis of G. The values in the graphs are 
means ± SD (error bars) of three independent experi-
ments. *, P < 0.05; **, P < 0.01 by t test compared 
with the control at each time point. Bars, 20 μm.DA-RAF1 IS REQUIRED FOR MYOGENIC DIFFERENTIATION • YOKOYAMA ET AL. 789
24–96 h in the differentiation medium (Fig. 7, D and E). The 
expression of another siRNA, M2, was less effective than that of 
M1 but signifi  cantly reduced the ratio of myogenin expression. 
In contrast, the expression of siRNAs R1 and R2 did not reduce 
the ratio. Both the expression of M1 and that of M2 almost 
completely suppressed myotube formation by cell fusion, and, 
consequently, myocytes with the knockdown of DA-Raf were 
mononucleated (Fig. 7, D and F). The mean number of nuclei in 
individual C2C12 cells expressing R1 or R2 was not so high 
(2.5–3 at 96 h). This is probably because myotubes generated 
by cell fusion of a small number of myoblasts are more easily 
detected than those generated by cell fusion of a large number of 
myoblasts as a result of limited transfection effi  ciency. Alto-
gether, these results imply that not only exogenously expressed 
DA-Raf1 but also intrinsic DA-Raf1 play crucial roles in the in-
duction of myocyte differentiation represented by cell cycle arrest, 
by the expression of myogenin and a set of late muscle-specifi  c 
proteins, and by cell fusion–mediated myotube formation.
Transfection of DAraf1 in C2C12 cells considerably re-
duced the ratio of the cells containing active phospho-ERK as 
detected by immunofl  uorescent staining (Fig. 8, A and B). In 
contrast, expression of the siRNA M1 or M2 facilitated the ratio 
of the cells containing phospho-ERK at 72 and 96 h in the dif-
ferentiation medium (Fig. 8, A and B). These results corroborate 
the notion that the function of DA-Raf1 to induce myocyte dif-
ferentiation is mediated by suppression of the ERK pathway.
Discussion
There are crucial differences among the canonical members of 
the Raf family (Raf-1, A-Raf, and B-Raf) in the regulatory 
mechanisms, target proteins, activities, and biological functions 
(Hagemann and Rapp, 1999; Mercer and Pritchard, 2003; 
Wellbrock et al., 2004). Furthermore, alternative splicing gener-
ates multiple splicing variants of B-Raf with different activities 
(Barnier et al., 1995; Papin et al., 1998). Nevertheless, all of the 
known Raf family proteins, including these splicing variants, share 
the three conserved regions CR1, 2, and 3. In marked contrast, 
DA-Raf1/2 that we have reported here almost exclusively comprises 
CR1, which encompasses Ras-binding and membrane-targeting 
Figure 7.  Suppression of the myogenic differ-
entiation phenotype in C2C12 cells by knock-
down of endogenous DA-Raf. (A) Knockdown 
of endogenous DA-Raf by mouse-speciﬁ   c 
siRNAs but not by rat-speciﬁ  c siRNAs in C2C12 
cells. The mouse-speciﬁ  c DAraf siRNAs (M1 and 
M2) and the rat-speciﬁ  c siRNAs (R1 and R2) 
were expressed in C2C12 cells by the retro  viral 
vector. The amounts of endogenous DA-Raf1 
were analyzed by immunoblotting with the anti–
  DA-Raf pAb. β-Tubulin is shown as a standard. 
(B) Prevention of the cell cycle arrest by RNAi of 
DAraf1/2 in C2C12 cells under the differentia-
tion condition. C2C12 cells were transfected 
with the empty pSilencer vector (control) or the 
siRNA-expressing pSilencer vectors together 
with pEGFP vector, cultured in the differentia-
tion medium for 48 h, and incubated with BrdU 
for 8 h. EGFP ﬂ  uorescence (green) monitoring 
the siRNA expression is merged with anti-BrdU 
staining (red). The cells expressing M1 or M2 
incorporated BrdU in the nuclei, but those ex-
pressing R1 or R2 did not. (C) Ratio of the BrdU-
incorporating C2C12 cells in the analysis of B. 
(D) Inhibition of myogenin expression and myo-
tube formation by RNAi of DAraf1/2 in C2C12 
cells. EGFP ﬂ  uorescence (green) monitoring the 
siRNA expression is merged with antimyogenin 
staining (red). The cells expressing M1 or M2 
were prevented from differentiation, but those 
expressing the rat-speciﬁ  c siRNAs (R1 and R2) 
were not. (E) Ratio of the myogenin-expressing 
cells in the analysis of D. (F) The number of nu-
clei in a C2C12 cell at 72 and 96 h in the dif-
ferentiation medium in the analysis of D. The 
values in the graphs are means ± SD (error bars) 
of three independent experiments. *, P < 0.05; 
**, P < 0.01 by t test compared with the control 
at each time point. Bars, 20 μm.JCB • VOLUME 177 • NUMBER 5 • 2007  790
RBD and CRD, and lacks CR2 and 3 representing the kinase 
domain. As expected from its structure, DA-Raf1 bound to active 
Ras and M-Ras and interfered with the ERK pathway. The bind-
ing to active Ras and M-Ras in vivo was confi  rmed by the fi  nd-
ings that DA-Raf1 was translocated to the cellular membranes to 
colocalize with Ras and M-Ras activated by mitogenic signals.
Induction of endogenous DA-Raf1 during C2C12 cell dif-
ferentiation was accompanied by reduction in the activating phos-
phorylation levels of MEK and ERK but not that of Akt. In 
addition, the exogenous expression of DAraf1 in v-Kras–trans-
formed fi  broblasts and in C2C12 myoblasts interfered with the 
Ras–ERK pathway but not with Ras–PI3K–Akt signaling. This is 
probably because the domains in Ras involved in the binding of Raf 
and PI3K p110 are partially overlapping but distinct (Rodriguez-
Viciana et al., 1997; Vetter and Wittinghofer, 2001). Thus, DA-
Raf1 is likely to compete with the binding of Raf proteins but 
not with that of PI3K p110. Consequently, DA-Raf1 may exclu-
sively antagonize the Ras–ERK pathway but not the signaling 
pathways of other target proteins. Several suppressor proteins of 
the Ras–ERK pathway have been identifi  ed, including Spry/Spred, 
RKIP, and IMP (Kim and Bar-Sagi, 2004; Odabaei et al., 2004; 
for reviews see Ory and Morrison, 2004; Mason et al., 2006). 
These proteins antagonize the Ras–ERK pathway by interacting 
with a variety of components of the growth factor receptor–Ras–
ERK pathway, but none of them directly bind to Ras. Thus, the 
mechanism of DA-Raf1 to interfere with the Ras–ERK pathway is 
unique and distinct from those of the other suppressor proteins.
Exogenously expressed DA-Raf1 suppressed all of the 
transformed phenotypes, including the tumorigenic potential 
of the v-Kras–transformed NIH3T3 fi  broblasts in nude mice. 
Accordingly, we can expect that DA-Raf1 might serve as a tumor 
suppressor protein if the gene has loss of function mutations or 
if the expression levels are noticeably reduced in tumors of cer-
tain tissues. Even if DA-Raf is not a bona fi  de tumor suppressor 
protein, it might be applicable for the treatment of Ras-induced 
tumors, which comprise 15–30% of human cancers (Mercer and 
Pritchard, 2003; Wellbrock et al., 2004), by promoting its ex-
pression or alternative splicing effi  ciency to generate DA-Raf1.
The binding of DA-Raf1 to Ras/M-Ras and suppression of 
the ERK pathway in the cells highly expressing DA-Raf1 imply 
that DA-Raf can serve as a dominant-negative antagonist of the 
Ras–ERK pathway. DA-Raf1 seems to bind to Ras/M-Ras faster 
and more easily than the typical Raf family members because of 
its small size and its structure that is comprised almost exclu-
sively of the RBD without regulatory sequences. The binding of 
DA-Raf1 to Ras/M-Ras may not be regulated by a variety of 
regulatory mechanisms for the typical Raf proteins, including 
phosphorylation and the binding of 14-3-3 proteins, scaffolding 
proteins such as KSR, and the suppressor proteins Spry and 
RKIP (Hagemann and Rapp, 1999; Chong et al., 2003; Mercer and 
Pritchard, 2003; Wellbrock et al., 2004). Thus, DA-Raf1 might 
accomplish the dominant-negative functions in vivo even if its 
amount is lower than those of the typical Raf proteins. A-Raf is 
specifi  cally located to mitochondria (Yuryev et al., 2000), whereas 
DA-Raf1 was diffusely present throughout the cytoplasm and 
translocated to the plasma membrane and vesicle membranes by 
the mitogenic signals. This suggests that DA-Raf1 exerts the 
dominant-negative functions against Raf proteins close to these 
membranes rather than against mitochondrion-associated A-Raf. 
Among the Raf family members, B-Raf is the main protein that 
couples Ras to MEK (Mercer and Pritchard, 2003; Wellbrock et al., 
2004), and this was true for C2C12 cells. In contrast, most of the 
signaling mechanisms and cellular functions of A-Raf remain 
enigmatic. Considering that DAraf1 is more highly expressed 
than Araf, particularly in the brain and myotubes, DA-Raf1 is the 
primary product of the Araf/DAraf gene by alternative splicing, 
at least in these tissues and cells. Furthermore, the binding of en-
dogenous DA-Raf1 to Ras lead to the decline in Ras–B-Raf inter-
action and B-Raf activity during C2C12 cell differentiation. 
Consequently, DA-Raf1 is likely to serve as the intrinsic dominant-
negative antagonist of the Ras–B-Raf–MEK–ERK pathway.
Because the amount of DA-Raf1 was prominently elevated 
during C2C12 cell differentiation, this elevated amount of 
Figure 8.  Suppression of ERK phosphorylation by DA-Raf1 and facilitation of 
ERK phosphorylation by the knockdown of endogenous DA-Raf during C2C12 
cell differentiation. (A) C2C12 cells were transfected with the pSilencer vectors 
expressing control scrambled siRNAs (control) or the siRNA M1 or M2 together 
with pEGFP vector. Other C2C12 cells were transfected with myc–DAraf1 and 
were cultured in the differentiation medium. EGFP ﬂ  uorescence (green) moni-
toring the siRNA expression or anti-myc staining detecting myc–DA-Raf1 ex-
pression (green) is merged with antiphospho-ERK1/2 staining (red). (B) Ratio 
of the cells with phospho-ERK1/2 in the analysis of A. The values in the graphs 
are means ± SD (error bars) of three independent experiments. *, P < 
0.05; **, P < 0.01 by t test compared with the control at each time point. 
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DA-Raf1 seems to be required to achieve the positive regulation 
of differentiation. Indeed, DA-Raf1 exogenously expressed in 
C2C12 cells facilitated myogenic differentiation by inducing 
myogenin and a set of late muscle-specifi  c protein expression as 
well as the cell cycle arrest. Moreover, the knockdown of endoge-
nous DA-Raf interfered with myogenic differentiation by sup-
pressing cell cycle arrest, myogenin expression, and myotube 
formation by cell fusion. Therefore, DA-Raf1 is essential for skel-
etal myocyte differentiation. This essential role of DA-Raf1 is 
probably through suppression of the Ras–ERK pathway because 
endogenous DA-Raf1 bound to Ras, and the B-Raf–MEK–
ERK pathway was suppressed during differentiation. Furthermore, 
overexpressed DA-Raf1 abrogated ERK activation, whereas the 
knockdown of DA-Raf facilitated ERK activation. The Ras–ERK 
pathway negatively regulates muscle-specifi  c gene expression by 
interfering with the expression of the MyoD family and MEF2 
family transcription factors (Lassar et al., 1989; Winter and 
Arnold, 2000; Perry et al., 2001; Tortorella et al., 2001). The Ras–
ERK pathway also counteracts the cell fusion and activation of 
Rb (Mittnacht et al., 1997; Peeper et al., 1997; Lee et al., 1999). 
Rb is required for myogenic differentiation by inducing not only 
the irreversible cell cycle arrest (Endo and Goto, 1992; Schneider 
et al., 1994; Novitch et al., 1996) but also the MEF2-dependent 
expression of late muscle-specifi  c proteins (Novitch et al., 1999). 
The Ras–ERK pathway causes the inactivation of Rb by trans-
activating cyclin D1 (Downward, 1997), which participates in inac-
tivating the phosphorylation of Rb by forming the complex with 
Cdk4/6. Insulin-like growth factors activate PI3K–Akt signaling 
that induces skeletal muscle myogenesis and hypertrophy (Glass, 
2003; Charge and Rudnicki, 2004). Thus, suppression of the Ras–
ERK pathway by DA-Raf1 without affecting Ras–PI3K–Akt sig-
naling is favorable for skeletal muscle cell differentiation.
Culturing skeletal muscle myoblasts under mitogen-poor 
differentiation conditions leads to inactivation of the Ras–ERK 
pathway and, consequently, results in myocyte differentiation. 
However, the mechanisms of this inactivation of the Ras–ERK 
pathway have not been fully understood. The prominent induc-
tion of DA-Raf1 and its binding to Ras under the differentiation 
condition and suppression of the Ras–ERK pathway by DA-
Raf1 explain the mechanisms of this inactivation of the Ras–
ERK pathway. The knockdown of DA-Raf by RNAi interfered 
with ERK activation and with myocyte differentiation under the 
differentiation condition. This implies that DA-Raf1 is indeed 
required for adequate inactivation of the Ras–ERK pathway for 
myocyte differentiation even under the mitogen-poor condition. 
We have unraveled the essential role of DA-Raf1 in skeletal 
muscle cell differentiation. Likewise, scrutiny of the cellular 
and physiological functions of DA-Raf in other cell types or 
tissues, in which DA-Raf is highly expressed or highly induced 
under particular conditions, may lead to the elucidation of un-
expected roles of this novel isoform of the Raf family.
Materials and methods
cDNA cloning
Mouse brain cDNA library constructed in pACT2 vector (CLONTECH Labora-
tories, Inc.) was screened by a yeast two-hybrid system with the constitu-
tively active rat Mras(G22V) cDNA (Matsumoto et al., 1997) ligated to the 
Gal4 DNA-binding domain in pGBD9 vector (CLONTECH Laboratories, 
Inc.). The yeast strain Y190 was transformed with the pGBT9/Mras(G22V) 
bait plasmid and then with the pACT2/cDNA library prey plasmids. 
Double transformants were selected on plates of the minimal synthetic dropout 
medium. Large colonies were further selected by β-galactosidase colony-
lift ﬁ  lter assay. The nucleotide sequence of the obtained 11 positive cDNA 
clones was determined with a DNA sequencing system (4200G; LI-COR). 
One of the cDNAs encoded mouse DA-Raf1. Rat and human DAraf1 
cDNAs were cloned from PC12 and HeLa cell mRNAs, respectively, by 
RT-PCR using Omniscript reverse transcriptase and ProofStart DNA polymer-
ase (QIAGEN). Primers used were sense primer 5′-G  A  C  A  A  C  A  T  G  G  A  A  C  C-
A  C  G  -3′ and antisense primer 5′-T  G  A  A  A  C  C  T  G  G  A  G  T  G  A  C  C  A  G  G  -3′ for 
rat DAraf1 and sense primer 5′-A  A  G  G  C  T  C  C  A  T  G  G  A  G  C  C  A  C  C  A  -3′ and 
antisense primer 5′-G  T  A  C  C  A  G  A  T  C  C  T  G  T  T  C  T  A  G  G  C  -3′ for human DAraf1. 
The sequences of mouse, rat, and human DAraf1 cDNAs have been deposited 
to the GenBank/ EMBL/DDBJ database with the accession nos. AB158252, 
AB158253, and AB158254, respectively.
RT-PCR and Northern blotting
RNAs were prepared from a variety of mouse tissues and from cultured 
cells as described previously (Endo and Nadal-Ginard, 1987; Abe et al., 
2003). Quantitative RT-PCR and Northern blotting were conducted as de-
scribed previously (Endo and Nadal-Ginard, 1987; Abe et al., 2003).
Antibody preparation and immunoblotting
Mouse DAraf1 cDNA was inserted into pQE32 vector (QIAGEN) in frame 
with the 6× His tag. The recombinant His-tagged DA-Raf1 was expressed 
in the Escherichia coli strain XL1-Blue and afﬁ  nity puriﬁ  ed with Talon Metal 
Afﬁ  nity Resin (CLONTECH Laboratories, Inc.). The protein was separated 
by SDS-PAGE and recovered from the gel. A New Zealand white rabbit 
was immunized with the puriﬁ   ed His–DA-Raf1 emulsiﬁ   ed with Freund’s 
complete or incomplete adjuvant (Difco Laboratories). The anti–DA-Raf 
pAb was afﬁ  nity puriﬁ  ed through formyl-celluloﬁ  ne (Seikagaku Corp.) 
coupled with the antigen. Mouse tissues were extracted with radioimmuno-
precipitation assay (RIPA) lysis buffer, their protein concentrations were 
determined by Bradford method, and the extracts were treated with SDS 
sample buffer. Cultured cells were directly lysed with the SDS sample buffer. 
These samples were subjected to SDS-PAGE and immunoblotting. Anti-
bodies used for the immunoblotting were the anti–DA-Raf pAb; pAbs to 
Raf-1, B-Raf, A-Raf (Santa Cruz Biotechnology, Inc.), MEK, phospho-MEK 
(Ser217/221), p44/42 MAPK, Akt, and phospho-Akt (Ser473; Cell Sig-
naling Technology); and mAbs to myogenin (F5D), MyHC (A4.1025), 
β-tubulin (E7; Developmental Studies Hybridoma Bank), TnT (NT302; Abe 
et al., 1986), and phospho-p44/42 MAPK (Thr202/Tyr204; E10; Cell 
Signaling Technology). The immunological reaction was detected with 
Western Lightning Chemiluminescence Reagent Plus (PerkinElmer) and 
analyzed with a luminoimage analyzer (LAS-1000mini; Fuji).
Pull-down assay
DAraf1 cDNA was inserted into pGEX-6P2 vector (GE Healthcare) in frame 
with the GST tag. The recombinant GST–DA-Raf1 was expressed in E. coli 
XL1-Blue and afﬁ  nity puriﬁ  ed with glutathione–Sepharose 4B (GE Healthcare). 
The cDNAs encoding the constitutively active and dominant-negative mutants 
of M-Ras and H-Ras as well as the v-Kras gene were fused in frame to the 
N-terminal myc tag in pEF-BOS/myc vector. These recombinant plasmids were 
transfected to COS-1 cells with FuGENE 6 Transfection Reagent (Roche). The 
cells were lysed, and the GST pull-down assay was conducted as described 
previously (Abe et al., 2003). Binding proteins were detected by immunoblot-
ting with the anti-myc mAb myc1-9E10 (American Type Culture Collection).
Coimmunoprecipitation assay
COS-1 cells were cotransfected with the recombinant plasmids pEF-BOS/
HA-DAraf1 and pEF-BOS/myc-Hras(G12V) or pEF-BOS/myc-Mras(G22V). 
24 h after the transfection, the cells were lysed with 800 μl of lysis buffer 
(10 mM Tris-HCl, pH 8.0, 150 mM NaCl, 5 mM MgCl2, 1% NP-40, 1 mM 
DTT, 0.1 mM PMSF, 2 μg/ml leupeptin, and 1 μg/ml pepstatin) and centri-
fuged at 16,000 g for 15 min. C2C12 cells cultured in the differentiation 
medium were lysed with the lysis buffer. Mouse brain was extracted with 
RIPA lysis buffer. The supernatant solutions were preabsorbed with protein G–
Sepharose 4 Fast Flow (GE Healthcare). Protein G–Sepharose was mixed 
with the mAb myc1-9E10 or mAb to H-Ras (238; Santa Cruz Biotechnology, 
Inc.) for 1 h and then mixed with the preabsorbed supernatant solution for 
1 h. The beads were washed ﬁ  ve times with the lysis buffer. Proteins bound 
to the beads were eluted with 9 M urea and detected by immunoblotting 
with the pAbs to HA tag (Medical and Biological Laboratories), DA-Raf, 
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In vitro kinase assay
C2C12 cells cultured in the differentiation medium were lysed with RIPA lysis 
buffer. B-Raf, Raf-1, and A-Raf were immunoprecipitated with each speciﬁ  c 
pAb prebound to protein A–Sepharose 4 Fast Flow (GE Healthcare). The 
Sepharose beads were washed ﬁ  ve times with RIPA lysis buffer and sus-
pended in 20 μl of the assay buffer (20 mM MOPS, pH 7.2, 75 mM 
MgCl2, 25 mM EGTA, 25 mM glycerol 2-phosphate, 1 mM sodium or-
thovanadate, and 1 mM DTT) containing 0.5 μg of recombinant GST–
MEK1 (Upstate Cell Signaling Solutions). They were mixed with 20 μl of 
the assay buffer containing 0.74 MBq γ-[
32P]ATP (166.5 TBq/mmol; MP 
Biomedicals) and incubated for 30 min at 30°C. The supernatant was 
mixed with 40 μl of 2× SDS sample buffer and subjected to SDS-PAGE. 
Phosphorylation of MEK1 was detected by autoradiography and analyzed 
with a bioimaging analyzer (BAS-1500 Mac; Fuji).
Epitope-tagging immunoﬂ  uorescent localization
Mouse C2C12 myoblasts were cotransfected with pEF-BOS/HA-DAraf1 
and pEF-BOS/myc-Hras or pEF-BOS/myc-Mras by using LipofectAMINE 
2000 (Invitrogen). 24 h after the transfection, the cells were cultured under 
a serum-free condition for 48 h and stimulated with 10% FBS or 50 ng/ml 
recombinant human FGF2 (Wako) for 30 min. They were ﬁ  xed with 4% 
PFA in PBS and permeabilized with 0.2% Triton X-100 in PBS. The cells 
were then incubated with the anti-HA tag pAb, the mAb myc1-9E10, and 
with AlexaFluor546-conjugated goat anti–rabbit IgG and AlexaFluor488–
goat anti–mouse IgG (Invitrogen). Fluorescent images were acquired at 
room temperature using a confocal laser-scanning microscope (LSM 410; 
Carl Zeiss MicroImaging, Inc.) with a 63× NA 1.40 plan-Apochromat ob-
jective lens and were assembled with Photoshop 9 (Adobe). In each plate, 
photographs were trimmed, and each ﬂ  uorochrome was adjusted identi-
cally for brightness and contrast to represent the observed images.
Cell transformation and transformation assays
The NRT9 cell line was established by stably transfecting the mouse 
NIH3T3 ﬁ   broblasts with the v-Kras gene in pLNCX vector (CLONTECH 
Laboratories, Inc.) followed by selecting with G418. To establish NRT9 cell 
clones stably transfected with DAraf1, an XbaI fragment of myc–DAraf1 in 
pEF-BOS/myc-DAraf1 was subcloned in pMIKHygB vector. The stable 
transfectants (NRT/DR cells) were selected with 500 μg/ml hygromycin B. 
The exogenously expressed myc–DA-Raf1 was detected by immunoblotting 
with the mAb myc1-9E10. The amounts of ERK1/2, Akt, and their activat-
ing phosphorylation levels were analyzed by immunoblotting with the 
p44/42 MAPK pAb, Akt pAb, phospho-p44/42 MAPK (Thr202/Tyr204) 
mAb E10, and phospho-Akt (Ser473) pAb, respectively. Cell morphology 
and actin cytoskeleton were analyzed by staining the cells with rhodamine–
phalloidin (Invitrogen). Focus formation assay and colony formation assay 
in soft agar were performed as described previously (Clark et al., 1995). 
To detect tumorigenicity, 1 × 10
6 cells were suspended in 100 μl of sterile 
PBS and subcutaneously injected into dorsal ﬂ  anks of nude mice. All mouse 
protocols were approved by the guidelines of Chiba University.
Skeletal myocyte differentiation
To induce terminal differentiation in C2C12 cells, undifferentiated myo-
blasts maintained in the growth medium (DME containing 10% FBS) were 
shifted to the differentiation medium (DME containing 5% horse serum) as 
described previously (Abe et al., 2003). The undifferentiated myoblasts 
were transfected with pEF-BOS/HA-DAraf1 in the growth medium and 
were left under the differentiation condition. DA-Raf1 and muscle-speciﬁ  c 
proteins (myogenin, MyHC, and TnT) were detected by staining with the 
anti-HA tag pAb and the mAbs to myogenin, MyHC, and TnT followed by 
AlexaFluor488–goat anti–rabbit IgG and AlexaFluor546–goat anti–mouse 
IgG. Fluorescent images were acquired at room temperature using a micro-
scope (Axioskop; Carl Zeiss MicroImaging, Inc.) with a 40× NA 1.30 
plan-Neoﬂ  uar objective lens, CCD camera (CoolSNAP; Roper Scientiﬁ  c), 
and Openlab 3.0.3 software (Improvision). The photographs were pro-
cessed with Photoshop 9 (Adobe) as described in the Epitope-tagging 
immunoﬂ  uorescent localization section.
RNAi
RNAi of DA-Raf was conducted by expressing siRNAs with pSilencer 2.1-
U6 neo vector (Ambion) as described previously (Sun et al., 2006). The 
target sequences of mouse DAraf siRNA M1 and M2 were 5′-A  A  A  G  A  A  G-
G  A  T  T  G  G  A  G  G  A  C  C  C  T  -3′ (nt 595–615 from the initiation codon) and 
5′-A  A  A  G  C  A  A  G  A  T  C  T  G  A  T  A  C  A  G  A  G  -3′ (nt 818–838), respectively. The target 
sequences of rat DAraf siRNA R1 and R2 were 5′-A  A  G  T  A  T  T  G  A  A  T  A  A  G  G  G-
C  A  T  G  G  -3′ (nt 670–690; 90.5% homologous to the corresponding mouse 
sequence) and 5′-A  A  C  A  A  G  A  T  C  T  G  A  T  G  T  A  G  A  G  T  G  -3′ (nt 820–840; 85% 
homologous to the corresponding mouse sequence), respectively. C2C12 
myoblasts were cotransfected with these siRNA-expressing pSilencer vec-
tors and one tenth of the amount of pEGFP-C1 vector (CLONTECH Labora-
tories, Inc.) to monitor the cells expressing siRNAs. They were shifted to the 
differentiation medium 24 h after the transfection and were cultured for a 
further 96 h. To assess the interfering effect of these siRNAs, pSilencer 5.1-
U6 Retro vector (Ambion) expressing these siRNAs was constructed, and 
the retroviruses were produced. C2C12 cells were infected with these retro-
viruses, and infected cells were selected with puromycin. Lysates of the selected 
cells cultured in the differentiation medium were subjected to immunoblotting 
with the anti–DA-Raf pAb.
Cell cycle determination
Proliferating or cell cycle–arrested cells were determined by the incorpora-
tion of BrdU. C2C12 myoblasts transfected with pEF-BOS/HA-DAraf1 
were cultured for 24 h in the growth medium. Then, they were incubated 
for 2 h in the same medium supplemented with 10 μM BrdU and 1 μM 
5-ﬂ  uoro 2′-deoxyuridine. C2C12 cells transfected with the pSilencer plas-
mids encoding DAraf siRNAs together with one tenth of the amount of 
pEGFP-C1 vector were cultured for 24 h in the growth medium. They were 
shifted to the differentiation medium and cultured for 48 h and for 8 h in 
the same medium supplemented with BrdU/5-ﬂ  uoro 2′-deoxyuridine. The 
BrdU-incorporating nuclei were detected by staining with an anti-BrdU 
mAb (GE Healthcare) supplemented with 10 μg/ml DNase I followed by 
AlexaFluor546–goat anti–mouse IgG.
Online supplemental material
Fig. S1 shows the colocalization of DA-Raf1 with constitutively active H-Ras 
and M-Ras but not with dominant-negative H-Ras and M-Ras. Fig. S2 indi-
cates the nucleotide sequences and corresponding amino acid sequences 
of rat and human DA-Raf1/2. Fig. S3 shows the suppression of ERK 
phosphorylation without affecting Akt phosphorylation in C2C12 myo-
blasts and suppression of the v–K-Ras–induced transformed phenotype in 
NRT9 cells by DA-Raf1. Online supplemental material is available at 
http://www.jcb.org/cgi/content/full/jcb.200703195/DC1.
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